These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 10407088

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Characteristic subcellular distribution, in brain, heart and lung, of biperiden, trihexyphenidyl, and (-)-quinuclidinyl benzylate in rats.
    Ishizaki J, Yokogawa K, Nakashima E, Ohkuma S, Ichimura F.
    Biol Pharm Bull; 1998 Jan; 21(1):67-71. PubMed ID: 9477171
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of sequence of administration on the pharmacokinetic interaction between the anticholinergic drug biperiden and [3H]quinuclidinyl benzylate or [3H]N-methylscopolamine in rats.
    Ishizaki J, Yokogawa K, Nakashima E, Takayasu T, Ohshima T, Ichimura F.
    J Pharm Pharmacol; 1998 Feb; 50(2):189-96. PubMed ID: 9530987
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung.
    Syvälahti EK, Kunelius R, Laurén L.
    Pharmacol Toxicol; 1988 Feb; 62(2):90-4. PubMed ID: 3353357
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of pro-amnesic efficacy of scopolamine, biperiden, and phencyclidine by using passive avoidance task in CD-1 mice.
    Malikowska N, Sałat K, Podkowa A.
    J Pharmacol Toxicol Methods; 2017 Jul; 86():76-80. PubMed ID: 28412329
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of anticholinergic drugs and brain muscarinic receptor alterations in streptozotocin diabetic rats.
    Nakashima E, Ishizaki J, Takeda M, Matsushita R, Yokogawa K, Ichimura F.
    Biopharm Drug Dispos; 1993 Nov; 14(8):673-84. PubMed ID: 8305628
    [Abstract] [Full Text] [Related]

  • 12. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
    Luthin GR, Wolfe BB.
    J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors.
    Nilvebrant L.
    Acta Pharmacol Toxicol (Copenh); 1986 Jul; 59 Suppl 1():1-45. PubMed ID: 3524114
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Heterogeneity of binding sites on cardiac muscarinic receptors induced by the neuromuscular blocking agents gallamine and pancuronium.
    Dunlap J, Brown JH.
    Mol Pharmacol; 1983 Jul; 24(1):15-22. PubMed ID: 6135150
    [Abstract] [Full Text] [Related]

  • 19. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
    Luthin GR, Wolfe BB.
    Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291
    [Abstract] [Full Text] [Related]

  • 20. Anti-nicotinic properties of anticholinergic antiparkinson drugs.
    Gao ZG, Liu BY, Cui WY, Li LJ, Fan QH, Liu CG.
    J Pharm Pharmacol; 1998 Nov; 50(11):1299-305. PubMed ID: 9877318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.